Milestone Scientific Reports Q3 2026 Results with Significant Medical Segment Growth
Milestone Scientific (MLSS) reported third-quarter 2026 results characterized by a strategic shift toward its medical segment. While total revenue declined 5.9% year-over-year to $2.2 million due to lower dental product sales, the medical segment saw explosive growth of 136%, driven by the clinical adoption of the CompuFlo system. The company successfully improved gross margins to 72.3% and reduced operating expenses by 15.3%. Management has identified an additional $400,000 in annual cost savings and expects to reach profitability by the fourth quarter of 2026 as revenue approaches the identified inflection point of $2.6 million to $2.7 million per quarter. Looking ahead, Milestone Scientific reaffirmed full-year revenue guidance of $9.8 million to $10.2 million. The company is also expanding its international footprint, having secured regulatory approval in Turkey and anticipating further approvals in Mexico and India by early 2027.
Tickers: $MLSS
Topics: Financial guidance Gross margin improvement Medical segment growth Net loss reduction Revenue decline